Journal Article

Ezetimibe Alone Reduces Low-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Combination Antiretroviral Therapy

David A. Wohl, David Waters, Ross J. Simpson, Susan Richard, Amanda Schnell, Sonia Napravnik, Jessica Keys, J. Joseph Eron and Priscilla Hsue

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 47, issue 8, pages 1105-1108
Published in print October 2008 | ISSN: 1058-4838
Published online October 2008 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/592116
Ezetimibe Alone Reduces Low-Density Lipoprotein Cholesterol in HIV-Infected Patients Receiving Combination Antiretroviral Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

In this crossover study of ezetimibe monotherapy in 48 antiretroviral-treated patients with human immunodeficiency virus infection, the mean changes in low-density lipoprotein cholesterol were −5.3% (−11 mg/dL) and +5.5% (+4 mg/dL) with ezetimibe treatment and placebo, respectively (P=.04). Ezetimibe was safe and effective in reducing low-density lipoprotein cholesterol and is an option for patients who cannot tolerate treatment with a statin.

Journal Article.  2532 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.